Search results for "Antibodies."

showing 10 items of 1857 documents

Epidemiology of hepatitis C virus infection in hemodialysis patients of Sicily

2008

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusBiomedical EngineeringMedicine (miscellaneous)BioengineeringHepacivirusmedicine.disease_causeBiomaterialsYoung AdultRenal DialysisEpidemiologymedicinePrevalenceHumansSicilyAgedAged 80 and overbusiness.industryGeneral MedicineHepatitis C AntibodiesHepatitis C ChronicMiddle AgedViral LoadVirologyChronic DiseaseRNA ViralFemaleKidney DiseasesHemodialysisbusiness
researchProduct

Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy

2004

Summary.  The Campania Region is a geographical area of southern Italy characterized by high incidence rates of hepatocellular carcinoma and of classic Kaposi's sarcoma. Epidemiological investigations carried out among different population groups in this region have found high prevalence rates of both hepatitis C virus (HCV) and human herpesvirus type 8 (HHV-8). To assess co-infection rates of HCV and HHV-8, we carried out a cross-sectional seroepidemiological study prevalence in Pomigliano d'Arco, a Health District of Campania located 20 km away from Naples. The overall rate of HCV/HHV-8 co-infection was 3.1%, 3.5% among men and 2.7% among women. No difference emerged in the HCV/HHV-8 co-i…

AdultMalemedicine.medical_specialtyvirusesHepatitis C virusPopulationAntibodies Viralmedicine.disease_causeSeroepidemiologic StudiesVirologyEpidemiologyHumansMedicineeducationAgededucation.field_of_studyHigh prevalenceHepatologybusiness.industryTransmission (medicine)Human herpes virusPublic healthvirus diseasesHerpesviridae InfectionsHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CVirologyCross-Sectional StudiesInfectious DiseasesItalyHepatocellular carcinomaHerpesvirus 8 HumanFemalebusinessJournal of Viral Hepatitis
researchProduct

Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy

2011

Abstract Background Hepatitis E virus (HEV) is a major cause of acute hepatitis in developing countries, whereas it is not considered a major health problem in Western World. Aims To investigate the spread of HEV and its possible role in causing acute hepatitis in Southern Italy. Methods Four hundred and thirty patients observed from April to December 2009 were studied and grouped as follows: 55 individuals with acute hepatitis (AH), 33 of whom cryptogenic; 321 individuals with chronic liver diseases (CLD), (278 Italians and 43 immigrants); 54 individuals without liver disease (control-group). Serum samples from all cases were tested for IgG anti-HEV antibodies and those positive to this te…

AdultMalemedicine.medical_specialtyvirusesmedicine.disease_causeZOONOSISHepatitisLiver diseaseCHRONIC LIVER-DISEASEYoung AdultHepatitis E virusEpidemiologymedicineHepatitis E virusHumansAcute hepatitisHepatitis AntibodiesHepatologybiologybusiness.industryLiver DiseasesGastroenterologyvirus diseasesMiddle AgedHepatitis Emedicine.diseaseSerum samplesVirologydigestive system diseasesHepatitis EImmunoglobulin MItalyImmunoglobulin GChronic Diseasebiology.proteinRNA ViralFemaleAntibodycryptogenic Acute HepatitisbusinessHepatitis E virus infectionAcute hepatitisSerological diagnosis Hepatitis E Virus Acute hepatitis ZOONOSIS CHRONIC LIVER-DISEASE cryptogenic Acute HepatitisSerological diagnosis
researchProduct

Analysis of cytokine and specific antibody profiles in hydatid patients with primary infection and relapse of disease

1998

We studied in vitro cytokine production by peripheral blood mononuclear cells (PBMC) from patients with primary and recurrent hydatid disease when cells were incubated with mitogen (PHA) and antigen from hydatid cyst fluid (HCFAg); levels of specific IgE, IgG4 and eosinophil counts were also measured in sera. When specifically stimulated, PBMC from patients produced higher levels of IL-2 (P < 0.02), IFN-γ (P < 0.0028) and IL-5 (P < 0.01) than those from uninfected donors, whereas IL-10 levels were comparable. Notably, IL-5 was also produced in higher levels (P < 0.01) by PBMC from patients when incubated with PHA. The IL-5:IFN-γ ratio was significantly greater (P < 0.02) when measured in re…

AdultMalemedicine.medical_treatmentImmunologyAntibodies HelminthBlood DonorsCell CountStimulationDiseaseImmunoglobulin EPeripheral blood mononuclear cellAntigenEchinococcosisRecurrencemedicineAnimalsHumansPhytohemagglutininsCells CulturedAgedbiologybusiness.industryMiddle AgedEosinophilIn vitroEosinophilsmedicine.anatomical_structureCytokineAntigens HelminthImmunologyLeukocytes Mononuclearbiology.proteinCytokinesCattleFemaleParasitologyMitogensbusinessCell DivisionParasite Immunology
researchProduct

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia

2011

Abstract Immune thrombocytopenia (ITP) is an autoimmune disease with a complex pathogenesis. As in many B cell–related autoimmune diseases, rituximab (RTX) has been shown to increase platelet counts in some ITP patients. From an immunologic standpoint, the mode of action of RTX and the reasons underlying its limited efficacy have yet to be elucidated. Because splenectomy is a cornerstone treatment of ITP, the immune effect of RTX on this major secondary lymphoid organ was investigated in 18 spleens removed from ITP patients who were treated or not with RTX. Spleens from ITP individuals had follicular hyperplasia consistent with secondary follicles. RTX therapy resulted in complete B-cell de…

AdultMalemedicine.medical_treatmentImmunologySplenectomySpleenT-Lymphocytes RegulatoryBiochemistryAntibodies Monoclonal Murine-DerivedImmune systemimmune system diseaseshemic and lymphatic diseasesHumansImmunologic FactorsMedicineImmunobiologyAgedAutoimmune diseaseB-LymphocytesPurpura Thrombocytopenic Idiopathicbiologybusiness.industryCell BiologyHematologyMiddle AgedTh1 Cellsmedicine.diseaseLymphatic systemmedicine.anatomical_structureImmunologyMonoclonalbiology.proteinFemaleRituximabAntibodyRituximabbusinessSpleenmedicine.drugBlood
researchProduct

Role of salivary anti-SSA/B antibodies for diagnosing primary Sjögren’s syndrome

2014

The diagnosis of primary Sjögren’s syndrome (pSS) is complex, and the saliva test is a potential method to improve the existing diagnostic criteria. Objective: To estimate the diagnostic accuracy of salivary anti-SSA/B antibodies in primary Sjögren’s syndrome (pSS), and to analyze their correlations with clinical and laboratory profiles. Study Design: This study enrolled 100 pSS patients and 140 non-pSS controls, including 40 rheumatoid arthritis (RA) patients, 40 systemic lupus erythematosus (SLE) patients, and 60 healthy controls. Unstimulated whole saliva and stimulated parotid saliva samples were collected from the subjects. Salivary anti-SSA/B antibodies were measured using an enzyme-l…

AdultMalemusculoskeletal diseasesSalivaAnti-nuclear antibodyOdontologíaAutoantigensstomatognathic systemSaliva testingHumansMedicineRheumatoid factorSalivaGeneral DentistryAutoantibodiesOral Medicine and Pathologybusiness.industryResearchAutoantibodyMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludeye diseasesstomatognathic diseasesSjogren's SyndromeRibonucleoproteinsOtorhinolaryngologySalivary diagnosticsRheumatoid arthritisImmunologyUNESCO::CIENCIAS MÉDICASFemaleSurgerybusinessAnti-SSA/Ro autoantibodies
researchProduct

Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study

2020

Abstract Aims To obtain safety and efficacy data of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting in high cardiovascular (CV) risk patients with heterozygous familial hypercholesterolaemia (HeFH) or very-high low-density lipoprotein cholesterol (LDL-C) levels despite maximally tolerated dose of statin ± other lipid-lowering therapies (MTD ± LLTs). ODYSSEY APPRISE was a prospective, single-arm, Phase 3b open-label (≥12 weeks to ≤ 30 months) European/Canadian study with alirocumab. Methods and results Patients received alirocumab 75 or 150 mg every 2 weeks, with dose adjustment based on physician’s judgment. In total, 994 patients were enrolled …

AdultMalemyalgiaCanadamedicine.medical_specialtyStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedReal life setting03 medical and health sciences0302 clinical medicineDose adjustmentInternal medicinemedicineHumansIn patientProspective Studies030212 general & internal medicineAdverse effectAgedAlirocumabbusiness.industryIncidence (epidemiology)Middle AgedTreatment OutcomeFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean Journal of Preventive Cardiology
researchProduct

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in German…

2013

Objective The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. Methods The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud’s and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, th…

AdultMalemyalgiamedicine.medical_specialty610 MedizinCohort StudiesAntibodies Monoclonal Murine-DerivedRheumatologyRefractoryInternal medicineHumansLupus Erythematosus SystemicMedicineIn patientskin and connective tissue diseasesRetrospective Studiesddc:610Proteinuriabusiness.industryOff-Label UseSystemic lupus erythematosus; rituximab; efficacy; safety;Blymphocytes; cohort studiesDiscontinuationCohortPhysical therapyFemaleRituximabmedicine.symptomRituximabbusinessCohort studymedicine.drugLupus
researchProduct

Increased seroprevalence of parvovirus B 19 IgG in complex regional pain syndrome is not associated with antiendothelial autoimmunity

2005

The etiology of complex regional pain syndrome (CRPS) is unclear yet. Recently autoantibodies and antecedent viral infections have been discussed to be involved in the pathogenesis of CRPS. We investigated sera from 39 CRPS patients and healthy controls for parvovirus B19 IgG and the occurrence of antiendothelial autoantibodies (AECA). CRPS patients showed a higher seroprevalence of parvovirus B19 IgG than controls (p < 0.01). All CRPS 2 patients were positive. 10.2% of the CRPS patients and 10.0% of the controls had AECA (n.s.) and AECA were not associated with parvovirus B19 seropositivity. Our findings suggest the involvement of parvovirus B19, but not autoantibody-mediated endothelial c…

AdultMalevirusesEnzyme-Linked Immunosorbent AssayAntibodies Viralmedicine.disease_causeAutoimmune DiseasesAutoimmunityParvoviridae InfectionsPathogenesisSeroepidemiologic StudiesParvovirus B19 HumanmedicineHumansSeroprevalenceEndotheliumAgedAutoantibodiesbiologybusiness.industryParvovirusAutoantibodyvirus diseasesMiddle Agedbiology.organism_classificationmedicine.diseaseAnesthesiology and Pain MedicineComplex regional pain syndromeImmunoglobulin GImmunologybiology.proteinEtiologyFemaleAntibodybusinessComplex Regional Pain SyndromesEuropean Journal of Pain
researchProduct

Molecular Cloning, Expression, Self-Assembly, Antigenicity, and Seroepidemiology of a Genogroup II Norovirus Isolated in France

2003

ABSTRACT Virus-like particles of Dijon171/96 virus, a genogroup II norovirus, were expressed in a baculovirus system and were used for a seroepidemiological study of 1,078 age-stratified human sera collected in Dijon, France. The results showed a seroprevalence of 74.1%. Furthermore, we showed that murine antibodies generated against recombinant Dijon171/96 virus, and human antibodies recognized discontinuous epitopes on the particles.

AdultMicrobiology (medical)AntigenicityAdolescentvirusesMolecular Sequence DataEnzyme-Linked Immunosorbent AssayAntibodies Viralmedicine.disease_causeEpitopeVirusSerologyMiceVirus-like particleSeroepidemiologic StudiesVirologymedicineAnimalsHumansSeroprevalenceCloning MolecularSerotypingChildAgedCaliciviridae InfectionsbiologyInfantMiddle Agedbiology.organism_classificationVirologyCaliciviridaeChild PreschoolImmunoglobulin GSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationNorovirusCapsid ProteinsElectrophoresis Polyacrylamide GelFranceCaliciviridaeJournal of Clinical Microbiology
researchProduct